2022
- The Marker: HDSA’s 2022 Research Report is now available
- HDSA Community Statement: FY23 Omnibus Appropriations Package Fails HD Families
- HDBuzz: Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
- Novartis provides status of VIBRANT-HD, the study of branaplam/LMI070 in Huntington’s disease
- Teresa Srajer Appointed Chair of HDSA’s National Board of Trustees
- Team HDSA Raises More Than $100,000 at the New York City Marathon
- Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine
- HDSA Awards $886,785 to Huntington’s Disease Human Biology Projects
- Breaking News: uniQure provides update on AMT-130
- Eighth Annual Freeze HD Raises More Than $200,000
- PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
- Three-year study shows that AUSTEDO® is safe, tolerable, and controls chorea in people with HD
- HDSA Publishes 2021 Annual Report
- HDBuzz: Forward momentum for Roche & Wave in latest news about huntingtin-lowering trials
- Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial
- BREAKING NEWS: Roche/Genentech Announce Plans For GENERATION-HD2
- HDSA Disability Chat: JHD & Social Security
- HDSA Research Webinar: All You Need To Know About PROOF-HD
- HDBuzz: Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
- Novartis Provides Community Update Regarding VIBRANT-HD
- HDSA Research Webinar: HD Clinical Trials Update
- Now Accepting 2023 HDSA Centers of Excellence Letters of Intent
- Sage Therapeutics Provides Positive Update on the SURVEYOR Study
- HDSA Films presents KING’S CRUSADE (Part 2)
- HDSA Statement Regarding VIBRANT-HD Trial
- uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
- HDSA Films presents KING’S CRUSADE (Part 1)
- Highlights from CHDI’s 17th Annual Huntington’s Disease Therapeutics Conference
- HDSA Awards 2022 Berman-Topper Family HD Career Development Fellowship
- uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- HDBuzz: How clever computers are helping us understand Huntington’s disease
- New system that defines Huntington’s disease will ‘revolutionise’ drug trials
- HDBuzz: A new roadmap to track Huntington’s disease progression
- 37th Annual HDSA Convention In Atlanta Brings The Global Huntington’s Disease Community Together Again
- Annexon Biosciences announces positive results from a Phase 2 clinical trial evaluating ANX005 in people with HD
- HDSA Films presents THE STORY OF E.J. + KATY
- HDSA Wins 2022 HD Hockey Classic & Raises More Than $15,000
- HDSA Announces Winners of the 2022 Donald A. King Summer Research Fellowship
- PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington’s Disease
- HDBuzz: A spoonful of branaplam helps the huntingtin go down
- HDBuzz: Day 3 of the 2022 HD Therapeutics Conference
- HDBuzz: Day 2 of the 2022 HD Therapeutics Conference
- HDBuzz: Day 1 of the 2022 HD Therapeutics Conference
- Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage’s Investigational Drug, SAGE-718.
- HDBuzz: Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
- Huntington’s Disease Society of America Awards Nearly $1.9 Million to Network of Fifty-Five HDSA Centers Of Excellence
- uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
- HDBuzz: Oral drug may change the story for huntingtin lowering
- Register Today for the 37th Annual HDSA Convention in Atlanta
- HDSA Publishes 2021 Year In Review Magazine
- BREAKING NEWS: Novartis Provides Community Update On The Status Of The VIBRANT-HD Trial
- VIDEO: Roche Community Presentation of New Tominersen Data
- BREAKING NEWS: Roche Has Announced That The Tominersen Research Programme Will Continue With A New Phase II Trial
- Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment
